541 related articles for article (PubMed ID: 24685414)
1. Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: a randomized, double blind, placebo controlled clinical trial.
Chand KS; Manchanda RK; Mittal R; Batra S; Banavaliker JN; De I
Homeopathy; 2014 Apr; 103(2):97-107. PubMed ID: 24685414
[TBL] [Abstract][Full Text] [Related]
2. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
7. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
[TBL] [Abstract][Full Text] [Related]
8. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
[TBL] [Abstract][Full Text] [Related]
9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
10. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
Tan S; Ding X; Tan Y; Cai X; Li Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.
Katiyar SK; Bihari S; Prakash S; Mamtani M; Kulkarni H
Int J Tuberc Lung Dis; 2008 Feb; 12(2):139-45. PubMed ID: 18230245
[TBL] [Abstract][Full Text] [Related]
12. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
13. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
[TBL] [Abstract][Full Text] [Related]
14. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.
Yan L; Kan X; Zhu L; Xu K; Yin J; Jie L; Li Y; Yue J; Cui W; Du J; Wang L; Tan S; Jiang X; Zeng Z; Xu S; Wang L; Chen Y; He W; Gao X; Bai D; Zhao C; Yan X; Zhu Y; Fan Y; Xie L; Deng A; Zhang Q; Xiao H
Clin Ther; 2018 Mar; 40(3):440-449. PubMed ID: 29519716
[TBL] [Abstract][Full Text] [Related]
15. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Dhingra VK; Rajpal S; Mittal A; Hanif M
Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
[TBL] [Abstract][Full Text] [Related]
17. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
[TBL] [Abstract][Full Text] [Related]
18. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.
Meyvisch P; Kambili C; Andries K; Lounis N; Theeuwes M; Dannemann B; Vandebosch A; Van der Elst W; Molenberghs G; Alonso A
PLoS One; 2018; 13(7):e0200539. PubMed ID: 30024924
[TBL] [Abstract][Full Text] [Related]
20. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
